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Abstract 
BACKGROUND: Diabetes and malignancy are two chronic diseases that have a major impact on the healthy 
population in developing countries, both contribute to the increase of morbidity and mortality of the patients. 
Diabetes presented with hyperglycemia due to insufficiency or resistance of insulin has been associated with an 
increased risk of thrombosis. Malignancy or cancer is number two killer in the developing countries after infectious 
diseases, one of the most common cause of death in cancer despite the disease itself is thrombosis, which 
occurred frequently as cancer cause changes in tumor biology, abnormal vascularisation, endothelial dysfunction, 
activation of coagulation and inflammation. Poor glucose control reflects by HbA1C has a significant correlation 
with a hypercoagulable state. 
AIM: This study was to evaluate the relation between hypercoagulable state and glycemic control in diabetic 
patients with malignancy. 
METHODS: This is a case control study, eighty samples of diabetes (40 samples were diabetes with malignancy) 
were collected from private hospitals and clinics. HbA1c, blood glucose level and Ddimer were measured. 
RESULTS: The forty five percent of the blood glucose level of the samples was not well controlled.  Sixty five 
percent of the samples in this group were norm weight, overweight 20% and obese 10%. The Ddimer levels were 
elevated in both groups and there was a significant correlation between HbA1C and Ddimer (p-0.046), blood 
glucose and age (p = 0.017). 
CONCLUSION: Chronic hyperglycemia will increase the risk of hypercoagulable state, that will also increase the 
morbidity and mortality rate in diabetes with malignancy patients. 
 
 
 
 
 
Introduction 
 
Diabetes Mellitus (DM) and malignancy are 
two chronic diseases that have major impact on health 
population, both contribute to the increase of morbidity 
and mortality of the patients. Diabetes Mellitus, a 
chronic metabolic disorder presented with 
hyperglycemia due to insufficiency or resistency of 
insulin, is considered one of the largest non-infectious 
health problems in the world, it is estimated there will 
be 300 million of people with diabetes in 2025 with the 
most in developing countries [1].
 
The prolonged hyperglycemia in diabetes will 
impaired and damaged various human organ systems 
[2], [3].
 
The endothelial cell dysfunction, haemostatic 
disorders, hypercoagulable state and thrombosis were 
the main complications that increase the morbidity in 
diabetes [4]. 
Malignancy or cancer is number two killer in 
developing countries after infectious diseases. One of 
the most common cause of death in cancer despite 
the disease itself is thrombosis [5]
 
which occurred 
occurred frequently as cancer cause changes in tumor 
biology, abnormal vascularisation, endothelial 
dysfunction, activation of coagulation and 
inflammation, besides the cancer itself causes 
increase activity of the procoagulant factors such as 
tissue factors, platelets and leucocytes. These explain 
the pathogenesis of thrombosis in cancer patients [6], 
[7].
 
Tumor tissue can activate blood coagulation and 
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malignancy transformation are also involved in the 
regulation of caogulant factors in tumor cells [8].
 
Patients with malignancy and DM shared the 
same variety of co-morbid which can increase 
morbidity and death, one of the most common is 
thrombosis that involving both the arteries and veins. 
Abnormalities in endothelial cells and a tendency of 
thrombosis may cause atherosclerosis and its 
complications. In normal circumstances endothelial 
cells produce the substances needed to maintain 
blood vessel homeostasis and preventing thrombosis 
[9].
 
Overweight and obesity that affect the 
majority of adults are increasing rapidly worldwide, 
driving the global diabetes epidemic [9].
 
Increase in 
body fat is generally associated with increased risk of 
metabolic diseases likes diabetes type 2 [10].
 
Body 
mass index were used to determine the presence or 
absence of obesity related comorbid disease [11]. 
This study was aimed to evaluate the relation 
between hypercoagulable state and glycemic control 
in diabetic patients with malignancy. 
 
 
Methods 
 
This is a case control study, eighty samples 
diabetes (40 samples were diabetes with malignancy) 
were collected from private hospitals and clinics. 
Malignancy cases were all solid tumor, diagnosed with 
pathology report, and diabetes was determined with 
the blood glucose ad random above 140 mg/dl and 
HbA1C. 
 
Laboratory measurements 
HbA1C was measured using an HPLC assay, 
blood glucose using spectrophotometry, 
hypercoagulable state was estimated by determining 
the Ddimer level using ELISA (Enzyme Linked 
immunosorbent assay). 
Body mass index were determined by 
calculating body weight and height according to the 
standardized protocols [24]. All datas were analyzed 
by using SPSS 22. 
 
Ethics, consent, and permissions  
This study has been approved by the Medical 
Ethical Committee of Medical Faculty University of 
Sumatera Utara Medan Indonesia. All participants 
were provided with written informed consent before 
study. 
 
Results 
 
Eighty samples with diabetes, in which 40 
samples were with malignancy, were recruited. 
Table 1: Characteristic of the diabetes with malignancy 
samples 
 N Range Minimum Maximum Mean Std. Deviation 
Hba1c 40 8.70 5.4 14.1 8.5 2.6 
Blood glucose 40 465 92 557 242 122 
Ddimer 40 4.28 .2 4.5 1.3 1.04 
BMI 40 23.37 14 38 25 4.08 
Age 40 40 45 85 60 8.9 
 
In this group they were 40 % male and 60 % 
female with the ages range from 45 years to 85 years 
old. Forty five percent of the blood sugar of the 
patients were poorly controlled. Sixty-two-point five 
percent of the patients have normal BMI, 27.5% 
overweight and 2.5% underweight, less are obese 
patients. 
Table 2: Characteristic of the diabetes samples 
 N Range Minimum Maximum Mean Std. Deviation 
HbA1C 40 10.3 2.4 12.7 7.6 2.3 
Blood glucose 40 552 83 635 260 105.53 
Ddimer 40 4.4 .13 4.5 1.3 1.1 
BMI 40 19 19 39 25 5 
Age 40 36 37 73 57 8.8 
 
 In the diabetic group there were 40 % male 
and 60% female. Forty five percent of the samples 
blood glucose was not well controlled as in the 
diabetes with malignancy group. Sixty five percent of 
the samples in this group were normoweight, 
overweight 20% and obese 10%, no underweight was 
found in this group. 
The Ddimer levels were elevated in groups, 
60% in the diabetes with malignancy group and 75% 
in the diabetes group. Mann-Whitney U test was used 
to analyze the HbA1c and Ddimer level between the 
diabetes patients and diabetes with malignancy 
patients, and it did not showed statistical significant (p 
= 0.08, p = 0.44). Correlation was calculated using the 
Spearman’s Rho correlation, and there was significant 
correlation between HbA1C and Ddimer (p-0.046), 
blood glucose and age (p = 0.017). 
In both group most of the samples were 
normoweight (60-62.5%), only in the diabetes with 
malignancy group got the underweight samples 
(2.5%). 
 
 
Discussion 
 
In this study, around forty five percent of the 
samples’ blood glucose were poorly controlled, this 
may because of the bad compliance, the disease itself 
like malignancy and medications. The chronic 
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uncontrollable glucose levels will worsen the 
hypercogulable state, this can be seen from the 
Ddimer levels that elevated in both groups, and from 
the statistical significant of the correlation between 
HbA1C and Ddimer. 
Body mass index did not showed any 
correlation with another variable in this study, maybe 
most of the samples were normoweight. 
In conclusion, most of the blood glucose 
levels were not well controlled in both groups. This 
should be encouraged in the health care system to 
improve the control of blood glucose. Both groups 
showed hypercoagulable state which can be seen 
from elevated of the Ddimer though did not showed 
statistical significant between group. 
There was statistical correlation between 
HbA1C and Ddimer, this should be an issue to be 
aware as chronic hyperglycemia will increased the risk 
of hypercoagulable, also the morbidity and mortality 
rate in diabetes with malignancy patients. 
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